Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Hansmann, G; Plouffe, BD; Hatch, A; von, Gise, A; Sallmon, H; Zamanian, RT; Murthy, SK.
Design and validation of an endothelial progenitor cell capture chip and its application in patients with pulmonary arterial hypertension.
J Mol Med (Berl). 2011; 89(10):971-83 Doi: 10.1007/s00109-011-0779-6 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Sallmon Hannes
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: The number of circulating endothelial progenitor cells (EPCs) inversely correlates with cardiovascular risk and clinical outcome, and thus has been proposed as a valuable biomarker for risk assessment, disease progression, and response to therapy. However, current strategies for isolation of these rare cells are limited to complex, laborious approaches. The goal of this study was the design and validation of a disposable microfluidic platform capable of selectively capturing and enumerating EPCs directly from human whole blood in healthy and diseased subjects, eliminating sample preprocessing. We then applied the "EPC capture chip" clinically and determined EPC numbers in blood from patients with pulmonary arterial hypertension (PAH). Blood was collected in tubes and injected into polymeric microfluidic chips containing microcolumns pre-coated with anti-CD34 antibody. Captured cells were immunofluorescently stained for the expression of stem and endothelial antigens, identified and counted. The EPC capture chip was validated with conventional flow cytometry counts (r = 0.83). The inter- and intra-day reliability of the microfluidic devices was confirmed at different time points in triplicates over 1-5 months. In a cohort of 43 patients with three forms of PAH (idiopathic/heritable, drug-induced, and connective tissue disease), EPC numbers are ≈50% lower in PAH subjects vs. matched controls and inversely related to two potential disease modifiers: body mass index and postmenopausal status. The EPC capture chip (5 × 30 × 0.05 mm(3)) requires only 200 μL of human blood and has the strong potential to serve as a rapid bedside test for the screening and monitoring of patients with PAH and other proliferative cardiovascular, pulmonary, malignant, and neurodegenerative diseases.
Find related publications in this database (using NLM MeSH Indexing): Adult - administration & dosage; Aged - administration & dosage; Aging - pathology; Body Mass Index - administration & dosage; Case-Control Studies - administration & dosage; Cell Count - administration & dosage; Cell Separation - administration & dosage; Endothelial Cells - pathology; Equipment Design - administration & dosage; Familial Primary Pulmonary Hypertension - administration & dosage; Female - administration & dosage; Humans - administration & dosage; Hypertension, Pulmonary - blood, diagnosis, pathology; Male - administration & dosage; Microfluidic Analytical Techniques - instrumentation, methods; Middle Aged - administration & dosage; Postmenopause - blood; Reproducibility of Results - administration & dosage; Stem Cells - pathology
Find related publications in this database (Keywords): Bioengineering; Vascular disease; Pulmonary; Endothelium; Bone marrow; Progenitor cells; Microfluidic device; Pulmonary hypertension; Biomarker; Bedside test; Diagnostics; Biomedical engineering